Cadence Pharmaceuticals
San Diego
About Cadence Pharmaceuticals
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. On May 4, 2010 Cadence resubmitted a New Drug Application for its investigational product candidate, OFIRMEVTM (acetaminophen) injection for the treatment of pain and fever in adults and children. The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) action date for OFIRMEV of November 4, 2010.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Total funding: $86.6M
- Funding stage: M&A
- Last round: Post-IPO Equity (Feb 2009)
- Ticker: nasdaq:CADX
- Website: cadencepharm.com
- Phone: 8584361401
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/cadence-pharmaceuticals-1041209 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.